Skip to main content
Clinical Trials/NCT04916548
NCT04916548
Completed
Phase 1

Repeated Neurocognitive Measurements in Depressed Patients

Rebecca Price1 site in 1 country15 target enrollmentSeptember 16, 2021

Overview

Phase
Phase 1
Intervention
Intravenous Ketamine
Conditions
Depression, Unipolar
Sponsor
Rebecca Price
Enrollment
15
Locations
1
Primary Endpoint
fMRI Intrinsic Connectivity: Limbic Network
Status
Completed
Last Updated
last year

Overview

Brief Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Registry
clinicaltrials.gov
Start Date
September 16, 2021
End Date
August 15, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Rebecca Price

Associate Professor of Psychiatry and Psychology

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • All participants will:
  • be between the ages of 18 and 60 years,
  • score ≥ 14 on the Hamilton Depression Rating Scale (Ham-D)
  • possess a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document

Exclusion Criteria

  • All participants:
  • Presence of lifetime bipolar, psychotic, or autism spectrum; current problematic substance use (e.g., ongoing moderate-to-severe substance use disorder);
  • Failure to meet standard MRI inclusion criteria: those who have cardiac pacemakers, neural pacemakers, cochlear implants, metal braces, or other non-MRI-compatible metal objects in their body. History of significant injury or surgery to the brain or spinal cord that would impair interpretation of results.
  • Acute suicidality or other psychiatric crises requiring treatment escalation. We will use the Columbia Suicide Severity Rating Scale (CSSRS) as both an initial exclusion criteria (CSSRS "Baseline/Screening" Version for past 1month period) and as grounds for rescue/removal (CSSRS "Since Last Visit" form). The CSSRS will be administered using a paper form by an experienced and thoroughly trained clinical assessor on the study team. Subjects with CSSRS suicide ideation scores scored "yes" on items 4 (active suicidal ideation with some intent to act) and/or 5 (active suicidal ideation with specific plan and intent) will be excluded from the study, and if enrolled, will be exited from the study and referred immediately to the nearest emergency mental health facility for additional thorough assessment and appropriate treatment referral.
  • Changes made to treatment regimen within 4 weeks of baseline assessment.
  • Reading level \<6th grade as per patient self-report.
  • Patients who have received ECT in the past 2 months prior to Screening.
  • Ketamine phase subsample additional exclusion criteria:
  • Patients currently taking any psychotropic medication.
  • Lifetime recreational ketamine or PCP use

Arms & Interventions

Intravenous Ketamine

Open-label ketamine infusion

Intervention: Intravenous Ketamine

Outcomes

Primary Outcomes

fMRI Intrinsic Connectivity: Limbic Network

Time Frame: 24hrs post-intervention

functional connectivity normalized correlation values within limbic network (range: -1 to +1; larger value = stronger connectivity, smaller value = weaker connectivity)

fMRI Intrinsic Connectivity: Frontoparietal Control Network

Time Frame: 24hrs post-intervention

functional connectivity normalized correlation values within frontoparietal control network (range: -1 to +1; larger value = stronger connectivity, smaller value = weaker connectivity)

fMRI Intrinsic Connectivity: Salience Network

Time Frame: 24hrs post-intervention

functional connectivity normalized correlation values within salience ventral attentional network (range: -1 to +1; larger value = stronger connectivity, smaller value = weaker connectivity)

fMRI Intrinsic Connectivity: Default Mode Network

Time Frame: 24hrs post-intervention

functional connectivity normalized correlation values within default mode network (range: -1 to +1; larger value = stronger connectivity, smaller value = weaker connectivity)

Secondary Outcomes

  • Quick Inventory of Depressive Symptoms(12 days post-intervention)
  • fMRI Intrinsic Connectivity: Dorsal Attention Network(24hrs post-intervention)
  • fMRI Intrinsic Connectivity: Somatosensory Motor Network(24hrs post-intervention)
  • fMRI Intrinsic Connectivity: Visual Network(24hrs post-intervention)
  • Montgomery-Asberg Depression Rating Scale(12 days post-intervention)
  • Hamilton Depression Rating Scale (Modified Score)(12 days post-intervention)

Study Sites (1)

Loading locations...

Similar Trials